Finota^®

Everolimus

Product Information

Proprietary Name: Finota®
Generic Name: Everolimus
Dosage Form: Tablet
Strengths: 5 mg, 10 mg
Indications: Hormone Receptor-Positive HER2-Negative Breast Cancer, Neuroendocrine Tumors (NET), Renal Cell Carcinoma (RCC), Tuberous Sclerosis Complex (TSC).

Download Leaflet

Oncology

Finota®

Everolimus is indicated for the treatment of hormone receptor-positive HER2-negative breast cancer, neuroendocrine tumors (NET), renal cell carcinoma (RCC), and tuberous sclerosis complex (TSC).